TOKYO —

A groundbreaking randomized clinical trial, the SINGLE-AF study, has provided compelling evidence that newer direct oral anticoagulants (DOACs) can substantially decrease serious cardiovascular events in individuals with atrial fibrillation (AF) who are classified as having an intermediate risk of stroke. The findings, presented at the prestigious ESC Congress 2026 and simultaneously published in the esteemed New England Journal of Medicine, represent a significant advancement in the management of this common cardiac arrhythmia, potentially reshaping clinical guidelines and treatment protocols.

The Persistent Challenge of Intermediate-Risk Atrial Fibrillation

Atrial fibrillation, characterized by an irregular and often rapid heart rate, affects millions worldwide and is a leading contributor to the formation of blood clots. These clots can dislodge and travel to the brain, causing a stroke, or to other parts of the body, leading to systemic embolism. The European Society of Cardiology (ESC) guidelines have long recommended oral anticoagulants as a cornerstone of treatment for AF patients identified as high risk for stroke, primarily assessed using the CHA2DS2-VASc score. However, for patients in the intermediate-risk category, the decision to initiate anticoagulant therapy has historically been a more nuanced and debated one.

Historically, the efficacy and safety of anticoagulants, particularly older vitamin K antagonist (VKA) drugs like warfarin, in this intermediate-risk group have yielded conflicting results in observational studies. This ambiguity created a clinical "gray area," leaving clinicians with less definitive guidance and patients with a degree of uncertainty regarding the optimal course of action. The SINGLE-AF trial was specifically designed to address this critical knowledge gap, aiming to provide robust randomized evidence on the benefits of newer DOACs in this previously less defined patient population.

Professor Boyoung Joung, the Principal Investigator of the SINGLE-AF trial and a distinguished figure from Yonsei University in Seoul, South Korea, articulated the rationale behind the study: "Evidence from observational studies with anticoagulants, particularly vitamin K antagonists, remains conflicting in those at intermediate risk. SINGLE-AF was conducted to provide the first evidence from a randomized trial on whether newer direct oral anticoagulants (DOACs) are beneficial in patients with AF at intermediate risk of stroke." The introduction of DOACs, such as apixaban and rivaroxaban, offered a potentially safer and more convenient alternative to VKAs due to their predictable pharmacokinetics, fixed dosing, and reduced need for routine monitoring.

Design and Execution of the SINGLE-AF Trial

The SINGLE-AF trial was an open-label, randomized controlled study that meticulously enrolled 1,803 participants across 18 medical centers in South Korea. The study focused on individuals diagnosed with atrial fibrillation who were assessed to have an intermediate risk of stroke. This intermediate risk was specifically defined by a CHA2DS2-VASc score of 1 in male participants and 2 in female participants, a common metric used to stratify stroke risk in AF patients.

Participants were allocated on a 1:1 ratio into two distinct treatment arms. The intervention group received treatment with modern direct oral anticoagulants. Specifically, patients in this arm were prescribed either apixaban 5 mg twice daily or rivaroxaban 20 mg once daily, depending on physician and patient preference and standard clinical practice. The comparator group, representing a crucial control arm, received no anticoagulant therapy. This design allowed for a direct comparison of the outcomes between patients receiving effective anticoagulation and those managed without it.

The open-label nature of the study, while sometimes associated with potential bias, was deemed acceptable by the researchers given the objective nature of the primary and secondary endpoints and the clear distinction between active treatment and no treatment. The robust sample size and the rigorous randomization process were designed to minimize confounding factors and ensure the reliability of the findings.

Landmark Findings: A Dramatic Reduction in Serious Events

The results of the SINGLE-AF trial, observed over a median follow-up period of 24 months, demonstrated a striking and statistically significant reduction in the composite primary endpoint. This endpoint was meticulously defined to capture a broad spectrum of serious adverse clinical outcomes, encompassing stroke, systemic embolism, major bleeding, and cardiovascular death.

Patients who received DOAC therapy experienced a remarkable 69% reduction in the incidence of these combined serious events when compared to the group that received no anticoagulation. This translates to a significant improvement in patient safety and a substantial decrease in the burden of cardiovascular morbidity and mortality.

Delving deeper into the data, the absolute incidence of serious events in the DOAC group was 0.5%, a stark contrast to the 1.5% observed in the no-anticoagulation group. This difference was statistically significant, with a p-value of 0.028 and a hazard ratio of 0.31 (95% confidence interval 0.10 to 0.94), indicating a strong protective effect of DOACs.

A key driver of this overall reduction in serious events was the significantly lower rate of ischemic strokes. Ischemic strokes, the most common type of stroke, occurred in only 0.1% of patients treated with DOACs, compared to a considerably higher 1.1% in the untreated group. This finding is particularly noteworthy, as stroke prevention remains a primary objective in the management of atrial fibrillation.

Crucially, the trial addressed a major concern associated with anticoagulant therapy: the risk of bleeding. The SINGLE-AF study found no statistically significant increase in major bleeding events between the two groups. Major bleeding occurred in 0.3% of patients receiving DOAC therapy and 0.5% of those who did not receive anticoagulation. This finding is of immense clinical importance, as it suggests that the substantial benefits in reducing thrombotic events can be achieved without a commensurate increase in the risk of dangerous bleeding complications, a concern that has often tempered the use of anticoagulants in certain patient populations.

Implications for Clinical Practice and Future Guidelines

The results of the SINGLE-AF trial carry profound implications for the clinical management of atrial fibrillation, particularly for the large cohort of patients who fall into the intermediate-risk category. The study provides the first definitive randomized evidence that directly supports the use of newer oral anticoagulants in this group, moving beyond the ambiguity of earlier observational data.

Professor Joung emphasized the transformative potential of these findings: "We now have evidence from a randomized trial that patients with AF at intermediate stroke risk benefit from DOAC therapy, without an increase in major bleeding. Data from the SINGLE-AF trial may be used to inform future guideline recommendations and reimbursement policies." This statement signals a clear path towards updating clinical practice guidelines, potentially leading to broader recommendations for DOAC initiation in intermediate-risk AF patients.

The broader impact extends beyond clinical decision-making. Reimbursement policies, which often lag behind clinical evidence, are likely to be influenced by these robust findings. This could lead to improved access to these life-saving medications for a larger patient population. The move towards more proactive and evidence-based treatment for intermediate-risk AF patients could prevent a significant number of strokes and other cardiovascular events, leading to improved patient outcomes, reduced healthcare costs associated with stroke management and long-term disability, and enhanced quality of life for those affected by atrial fibrillation.

The success of the SINGLE-AF trial also underscores the ongoing evolution of anticoagulant therapy. The shift from VKAs to DOACs has been a major development in cardiovascular medicine, offering improved convenience and, as demonstrated by this trial, significant clinical benefits in specific patient groups. Further research may continue to refine our understanding of optimal anticoagulant strategies across the full spectrum of AF risk, but SINGLE-AF has undoubtedly established a new benchmark for intermediate-risk patients.

Context and Background: A Timeline of Anticoagulant Evolution

The journey towards understanding optimal anticoagulation in AF has been a long and evolving one. For decades, warfarin was the gold standard, requiring meticulous monitoring of the International Normalized Ratio (INR) to ensure therapeutic efficacy and minimize bleeding risk. This process was often cumbersome for patients and clinicians, leading to periods of suboptimal anticoagulation due to fluctuations in INR.

The early 2000s saw the emergence of direct oral anticoagulants, initially targeting specific clotting factors like Factor Xa and thrombin. These newer agents, including dabigatran, rivaroxaban, apixaban, and edoxaban, were developed with the aim of overcoming the limitations of warfarin. Clinical trials like RE-LY (dabigatran), ROCKET-AF (rivaroxaban), ARISTOTLE (apixaban), and ENGAGE AF-TIMI 48 (edoxaban) established the non-inferiority or superiority of these DOACs over warfarin in high-risk AF populations, demonstrating comparable or reduced rates of bleeding and a reduction in stroke and systemic embolism.

However, the definitive evidence for their use in the intermediate-risk AF population remained elusive. Observational studies offered glimpses of benefit but were limited by confounding factors and the inherent biases of non-randomized data. The SINGLE-AF trial, by employing a robust randomized controlled design, was specifically designed to fill this void. The trial’s initiation in recent years reflects the ongoing commitment of the scientific community to refine and optimize the management of cardiovascular diseases based on the latest evidence. The presentation and publication of its findings in 2026 mark a pivotal moment in this ongoing narrative.

Broader Implications and Future Directions

The findings from the SINGLE-AF trial are not merely a footnote in the annals of medical research; they represent a paradigm shift in how intermediate-risk atrial fibrillation will be managed. The implications extend beyond the immediate patient population, influencing public health strategies, drug development, and the economic landscape of cardiovascular care.

Economic Impact: By preventing strokes and other serious cardiovascular events, the widespread adoption of DOACs in intermediate-risk patients could lead to substantial cost savings for healthcare systems. The cost of managing a stroke, including hospitalization, rehabilitation, and long-term care, is significant. Preventing these events through effective anticoagulation represents a more cost-effective approach in the long run.

Patient Empowerment: For patients previously in the "watchful waiting" category, the clear evidence of benefit and acceptable safety profile of DOACs will empower them and their clinicians to make more proactive treatment decisions. This can lead to reduced anxiety and a greater sense of control over their health.

Future Research: While SINGLE-AF provides a definitive answer for intermediate-risk patients, research will likely continue to explore nuances. This could include investigations into the optimal duration of therapy, personalized approaches based on genetic factors, and the combined use of DOACs with other cardiovascular medications. Furthermore, ongoing surveillance of real-world data will be crucial to monitor long-term safety and effectiveness.

In conclusion, the SINGLE-AF trial stands as a landmark achievement in cardiovascular research, offering clear, randomized evidence that direct oral anticoagulants are a safe and highly effective option for reducing serious cardiovascular events in patients with atrial fibrillation who are at intermediate risk of stroke. This pivotal study is poised to reshape clinical practice, influence future guideline development, and ultimately improve the lives of millions worldwide.